# A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19

> **NCT05616728** · PHASE2 · COMPLETED · sponsor: **Enanta Pharmaceuticals, Inc** · enrollment: 231 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** EDP-235
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05616728
- **Lead sponsor:** Enanta Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-10
- **Primary completion:** 2023-02-08
- **Final completion:** 2023-06-29
- **Target enrollment:** 231 (ACTUAL)
- **Last updated:** 2024-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05616728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05616728, "A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05616728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*